Short Interest in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Decreases By 8.6%

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) saw a significant drop in short interest during the month of April. As of April 15th, there was short interest totalling 20,200 shares, a drop of 8.6% from the March 31st total of 22,100 shares. Based on an average daily trading volume, of 2,900 shares, the short-interest ratio is presently 7.0 days. Approximately 1.0% of the shares of the company are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cyclerion Therapeutics stock. Tyndall Capital Partners L P purchased a new stake in shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 147,712 shares of the company’s stock, valued at approximately $505,000. Cyclerion Therapeutics accounts for about 100.0% of Tyndall Capital Partners L P’s holdings, making the stock its biggest holding. Tyndall Capital Partners L P owned 6.13% of Cyclerion Therapeutics as of its most recent filing with the SEC. Institutional investors and hedge funds own 75.62% of the company’s stock.

Cyclerion Therapeutics Price Performance

NASDAQ CYCN traded up $0.15 during trading hours on Monday, hitting $3.08. The company’s stock had a trading volume of 1,539 shares, compared to its average volume of 3,113. The company has a market cap of $8.35 million, a P/E ratio of -0.56 and a beta of 1.84. The company’s 50 day simple moving average is $3.10 and its two-hundred day simple moving average is $3.05. Cyclerion Therapeutics has a 12 month low of $1.75 and a 12 month high of $6.75.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.